ロード中...
Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8(+) and CD4(+) CD19-specific chimeric antigen receptor-modified T cells
CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that impact toxicity and efficacy have been difficult to define because of differences in lymphodepletion regimens and heterogeneity of CAR-T cells administered to individual pa...
保存先:
| 出版年: | Sci Transl Med |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5045301/ https://ncbi.nlm.nih.gov/pubmed/27605551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aaf8621 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|